Chembio Diagnostics, Inc.CE.MINASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank49
Year-over-Year Change
Year-over-year SG&A expense growth
Latest
22.33%
↓ 96% vs avg
Percentile
P49
Within normal range
Streak
1 qtr
Consecutive growthRecovering
Average
511.14%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 22.33% |
| Q3 2025 | -4.73% |
| Q2 2025 | 34.50% |
| Q1 2025 | 237.13% |
| Q4 2024 | -159.57% |
| Q3 2024 | 10800.63% |
| Q2 2024 | -100.94% |
| Q1 2024 | 253.09% |
| Q4 2023 | -143.50% |
| Q3 2023 | 1672.93% |
| Q2 2023 | -90.61% |
| Q1 2023 | 81.31% |
| Q4 2022 | -64.95% |
| Q3 2022 | 1447.88% |
| Q2 2022 | -88.83% |
| Q1 2022 | 269.84% |
| Q4 2021 | -138.60% |
| Q3 2021 | 1157.18% |
| Q2 2021 | -86.87% |
| Q1 2021 | 331.24% |
| Q4 2020 | -129.24% |
| Q3 2020 | 1023.67% |
| Q2 2020 | -84.85% |
| Q1 2020 | 284.59% |
| Q4 2019 | -131.24% |
| Q3 2019 | 593.73% |
| Q2 2019 | -74.62% |
| Q1 2019 | 234.60% |
| Q4 2018 | -139.42% |
| Q3 2018 | 914.46% |
| Q2 2018 | -82.61% |
| Q1 2018 | 231.21% |
| Q4 2017 | -145.15% |
| Q3 2017 | 1373.30% |
| Q2 2017 | -88.43% |
| Q1 2017 | 310.83% |
| Q4 2016 | -128.71% |
| Q3 2016 | 801.74% |
| Q2 2016 | -80.79% |
| Q1 2016 | 333.16% |